Cowen analyst Ken Cacciatore reiterated an Outperform rating and $30 price target on Foamix Pharmaceuticals (NASDAQ: FOMX), saying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE